CA3139508A1 - Materials and methods for modulating t cell mediated immunity - Google Patents

Materials and methods for modulating t cell mediated immunity Download PDF

Info

Publication number
CA3139508A1
CA3139508A1 CA3139508A CA3139508A CA3139508A1 CA 3139508 A1 CA3139508 A1 CA 3139508A1 CA 3139508 A CA3139508 A CA 3139508A CA 3139508 A CA3139508 A CA 3139508A CA 3139508 A1 CA3139508 A1 CA 3139508A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3139508A
Other languages
English (en)
French (fr)
Inventor
Rajkumar Ganesan
Iqbal S. Grewal
Sanjaya Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CA3139508A1 publication Critical patent/CA3139508A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3139508A 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity Pending CA3139508A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962844976P 2019-05-08 2019-05-08
US201962844966P 2019-05-08 2019-05-08
US201962844959P 2019-05-08 2019-05-08
US201962844995P 2019-05-08 2019-05-08
US201962844970P 2019-05-08 2019-05-08
US62/844,959 2019-05-08
US62/844,966 2019-05-08
US62/844,970 2019-05-08
US62/844,976 2019-05-08
US62/844,995 2019-05-08
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity

Publications (1)

Publication Number Publication Date
CA3139508A1 true CA3139508A1 (en) 2020-11-12

Family

ID=73051172

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3139508A Pending CA3139508A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity

Country Status (22)

Country Link
US (2) US11667712B2 (cg-RX-API-DMAC7.html)
EP (1) EP3965818A4 (cg-RX-API-DMAC7.html)
JP (2) JP7686571B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220017892A (cg-RX-API-DMAC7.html)
CN (1) CN113966231B (cg-RX-API-DMAC7.html)
AU (1) AU2020267504A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022089A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139508A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002905A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021015998A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210548A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000229A (cg-RX-API-DMAC7.html)
EC (1) ECSP21087921A (cg-RX-API-DMAC7.html)
IL (1) IL287817A (cg-RX-API-DMAC7.html)
JO (1) JOP20210297A1 (cg-RX-API-DMAC7.html)
MA (1) MA55903A (cg-RX-API-DMAC7.html)
MX (1) MX2021013532A (cg-RX-API-DMAC7.html)
PE (1) PE20220763A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552790A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112021QA (cg-RX-API-DMAC7.html)
TW (1) TW202108618A (cg-RX-API-DMAC7.html)
WO (1) WO2020227457A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
MX386714B (es) 2015-01-27 2025-03-11 Lava Therapeutics N V Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
JP7457007B2 (ja) 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用CD1d免疫グロブリン
JP7686571B2 (ja) 2019-05-08 2025-06-02 ヤンセン バイオテツク,インコーポレーテツド T細胞媒介性免疫を調節するための材料及び方法
JP2022545196A (ja) * 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗tcrデルタ可変1抗体の治療的使用
CA3173268A1 (en) * 2020-02-27 2021-09-02 Janssen Biotech, Inc. Materials and methods for modulating an immune response
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
US12076413B2 (en) 2020-10-28 2024-09-03 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity
CA3211114A1 (en) * 2021-02-16 2022-08-25 Janssen Biotech, Inc. Materials and methods for enhanced linker targeting
WO2022180271A1 (en) 2021-02-26 2022-09-01 LAVA Therapeutics N.V. Antibodies that bind CD123 and gamma-delta T cell receptors
JP2026526851A (ja) * 2023-07-26 2026-08-10 ヤンセン バイオテツク,インコーポレーテツド 細胞増殖のための材料及び方法
AU2024379650A1 (en) * 2023-11-15 2026-06-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Trgv9 binding proteins and medical use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク,インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP5996429B2 (ja) 2009-09-03 2016-09-21 ジェネンテック, インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2012018767A2 (en) 2010-08-05 2012-02-09 Anaptysbio, Inc. Antibodies directed against il-17
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
LT2748201T (lt) * 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
CN104203981A (zh) 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
US9907820B2 (en) * 2013-10-25 2018-03-06 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
DK3189081T3 (da) 2014-09-05 2020-05-04 Janssen Pharmaceutica Nv Cd123-bindende midler og anvendelser deraf
RU2756247C2 (ru) 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
EP3560955A4 (en) 2016-12-26 2020-12-23 Kyowa Kirin Co., Ltd. ANTIBODIES CAPABLE OF BINDING TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
WO2019147735A1 (en) * 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
BR112020023508A2 (pt) 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
JP7686571B2 (ja) 2019-05-08 2025-06-02 ヤンセン バイオテツク,インコーポレーテツド T細胞媒介性免疫を調節するための材料及び方法
CA3173268A1 (en) 2020-02-27 2021-09-02 Janssen Biotech, Inc. Materials and methods for modulating an immune response
US20210284731A1 (en) 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
PE20231517A1 (es) 2020-03-13 2023-09-28 Janssen Biotech Inc Materiales y metodos para la union de siglec-3/cd33
US12076413B2 (en) 2020-10-28 2024-09-03 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity

Also Published As

Publication number Publication date
CN113966231B (zh) 2025-04-01
CN113966231A (zh) 2022-01-21
WO2020227457A1 (en) 2020-11-12
ECSP21087921A (es) 2022-01-31
DOP2021000229A (es) 2022-07-31
MX2021013532A (es) 2022-02-11
CO2021015998A2 (es) 2021-12-10
KR20220017892A (ko) 2022-02-14
PH12021552790A1 (en) 2022-09-05
MA55903A (fr) 2022-03-16
EP3965818A1 (en) 2022-03-16
JP2024170410A (ja) 2024-12-10
US11667712B2 (en) 2023-06-06
US12673995B2 (en) 2026-07-07
CR20210548A (es) 2022-02-11
US20240150464A1 (en) 2024-05-09
JOP20210297A1 (ar) 2023-01-30
SG11202112021QA (en) 2021-11-29
AU2020267504A1 (en) 2021-12-02
CL2021002905A1 (es) 2022-06-17
TW202108618A (zh) 2021-03-01
JP2022533538A (ja) 2022-07-25
EP3965818A4 (en) 2023-05-31
JP7686571B2 (ja) 2025-06-02
PE20220763A1 (es) 2022-05-16
BR112021022089A2 (pt) 2022-02-08
IL287817A (en) 2022-01-01
US20210032338A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
US20240218076A1 (en) Therapeutic antibodies
CA3198590A1 (en) Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
CA2684626C (en) Penta-specific antibodies binding il-8, gro-alpha, gro-beta, gro-gamma and ena-78
CA3199767A1 (en) Compositions and methods for modulating delta gamma chain mediated immunity
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
US20170210802A1 (en) Multispecific antigen binding proteins
CN113573728A (zh) 治疗性SIRPα抗体
IL295295A (en) Antibodies targeting fc receptor-like 5 and methods of use
CA3120793A1 (en) Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof
CN113056487A (zh) 抗tnfr2抗体及其用途
AU2020267504A1 (en) Materials and methods for modulating T cell mediated immunity
CN116234572A (zh) 治疗性SIRPα抗体
JP7430137B2 (ja) 抗体および使用方法
CN118638234A (zh) 抗bdca2抗体及其制备方法和应用
KR20240036142A (ko) 3특이성 및/또는 3가 결합 단백질
JP2025537255A (ja) 抗アルファ5インテグリン抗体及びその使用
US20250340632A1 (en) SPECIFIC ANTAGONIST ANTI-SIRPg ANTIBODIES
WO2024094151A1 (en) Multi-specific antibody and medical use thereof
CN114773467B (zh) 抗SIRPα抗体或其抗原结合片段及应用
KR20240113488A (ko) 신규 항-il-36r 항체
TW202521578A (zh) Btn3a結合蛋白及其醫藥用途
JP2025532504A (ja) 抗ilt4抗体及びその医薬的使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220617

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241221

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241221

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250102

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250502

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250505

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250505

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260429